These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32612272)

  • 1. Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer.
    Delrieu L; Jacquet E; Segura-Ferlay C; Blanc E; Febvey-Combes O; Friedenreich C; Romieu G; Jacot W; Rios M; Heudel PE; Roemer-Becuwe C; Jouannaud C; Tredan O; Chaigneau L; Arnedos M; Orfeuvre H; Quenel-Tueux N; Jacquin JP; Ferrero JM; Moullet I; Abadie-Lacourtoisie S; Penault-Llorca F; Cox D; Bachelot T
    Sci Rep; 2020 Jul; 10(1):10757. PubMed ID: 32612272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
    Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
    Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab and survival of patients with metastatic breast cancer.
    Kast K; Schoffer O; Link T; Forberger A; Petzold A; Niedostatek A; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
    Arch Gynecol Obstet; 2017 Aug; 296(2):303-312. PubMed ID: 28616827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.
    Martel S; Poletto E; Ferreira AR; Lambertini M; Sottotetti F; Bertolini I; Montemurro F; Bernardo A; Risi E; Zanardi E; Ziliani S; Mura S; Dellepiane C; Del Mastro L; Minisini AM; Puglisi F
    Breast; 2018 Feb; 37():142-147. PubMed ID: 29161652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
    Gobbini E; Ezzalfani M; Dieras V; Bachelot T; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Cleaud AL; Robain M; Courtinard C; Cailliot C; Perol D; Delaloge S
    Eur J Cancer; 2018 Jun; 96():17-24. PubMed ID: 29660596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
    BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer.
    Ogiya R; Sagara Y; Niikura N; Freedman RA
    Clin Breast Cancer; 2019 Jun; 19(3):200-207.e1. PubMed ID: 30795886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum-containing regimens for metastatic breast cancer.
    Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
    Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
    Press DJ; Miller ME; Liederbach E; Yao K; Huo D
    Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.
    Kim MH; Kim GM; Kim JH; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Sohn J
    Breast Cancer Res Treat; 2020 Feb; 179(3):687-697. PubMed ID: 31811505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status.
    Bertaut A; Mounier M; Desmoulins I; Guiu S; Beltjens F; Darut-Jouve A; Ponnelle T; Arnould L; Arveux P
    Eur J Cancer Care (Engl); 2015 Nov; 24(6):920-8. PubMed ID: 25757548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Significance of Tumor Subtypes in Women With Breast Cancer According to Stage: A Population-based Study.
    Leone JP; Leone J; Zwenger AO; Vallejo CT; Leone BA
    Am J Clin Oncol; 2019 Jul; 42(7):588-595. PubMed ID: 31166208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Energy balance and breast cancer risk: a prospective cohort study.
    Silvera SA; Jain M; Howe GR; Miller AB; Rohan TE
    Breast Cancer Res Treat; 2006 May; 97(1):97-106. PubMed ID: 16319973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
    Todorovic-Rakovic N; Neskovic-Konstantinovic Z
    J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
    Toomey S; Madden SF; Furney SJ; Fan Y; McCormack M; Stapleton C; Cremona M; Cavalleri GL; Milewska M; Elster N; Carr A; Fay J; Kay EW; Kennedy S; Crown J; Gallagher WM; Hennessy BT; Eustace AJ
    Oncotarget; 2016 Nov; 7(46):75518-75525. PubMed ID: 27776352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
    McCarthy AM; Kumar NP; He W; Regan S; Welch M; Moy B; Iafrate AJ; Chan AT; Bardia A; Armstrong K
    BMC Cancer; 2020 Apr; 20(1):347. PubMed ID: 32326897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
    Harbeck N; Huang CS; Hurvitz S; Yeh DC; Shao Z; Im SA; Jung KH; Shen K; Ro J; Jassem J; Zhang Q; Im YH; Wojtukiewicz M; Sun Q; Chen SC; Goeldner RG; Uttenreuther-Fischer M; Xu B; Piccart-Gebhart M;
    Lancet Oncol; 2016 Mar; 17(3):357-366. PubMed ID: 26822398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.